Memic Announces Multiple Upcoming Presentations of Hominis Surgical System at Society of Robotic and Digital Surgery 2022 Annual Meeting

Memic Innovative Surgery Ltd. (Memic), a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that multiple abstracts detailing clinical data related to the Hominis Surgical System for robotic-assisted transvaginal hysterectomy were accepted for presentation at the Society of Robotic and Digital Surgery (SRS) 2022 Annual Meeting, taking place June 30-July 3 at the Disney Yacht & Beach Club Resort in Florida.

Details of the Memic presentations at SRS are as follows:

Fireside Chat

Title: Fireside Chat: Pioneering New Platforms in Surgical Robotics: Memic, Senhance, Insightec

Presenter: Dvir Cohen, CEO, Memic

Date and Time: Thursday, June 30, 2022 from 12:45-1:15 p.m. ET

Location: Asbury A-C

Oral Presentations

Title: The Future of Soft Tissue Robotics is Now

Presenter: Michael A. Conditt, PhD, senior vice president, strategic marketing & clinical development, Memic

Date and Time: Friday, July 1, 2022 from 8:15-8:30 a.m. ET

Location: Asbury A-C

Title: Hominis Robotic Platform: Vaginal Robotics

Presenters: Ricardo E. Estape, MD, gynecologic surgeon and director, HCA Florida Institute for Gynecologic Oncology, Kendall Hospital and Erica Stockwell, DO, MBA, FACOG, gynecologic surgeon, AdventHealth Celebration

Date and Time: Saturday, July 2, 2022 from 1:30-1:40 p.m. ET

Location: Asbury D

Title: Design of a Robotic Surgery Console to Optimize User Ergonomics

Presenters: Thomas P. Heffernan, MD, gynecologic oncologist, Medical City Plano; Dr. Estape; Daniel Z. Michaeli, user experience lead, Memic; Matthew T. McKittrick, MBA, strategic marketing, Memic; and Dr. Conditt
Date and Time: Friday, July 1, 2022 from 4:20-5:00 p.m. ET

Location: Asbury D

Poster Number: G-9

Title: Quantifying a Comprehensive Training Protocol for a Novel Transvaginal Robotic System

Presenters: Dr. Stockwell, Dr. Conditt and Michael A. Hall, senior director, professional education, Memic

Date and Time: Friday, July 1, 2022 from 4:20-5:00 p.m. ET

Location: Asbury D

Poster Number: G-8

Poster Presentations

Title: Novel Single-port Robotic Platform for Bilateral Inguinal Hernia Repair

Authors: Eduardo Parra-Davila, MD, FACS, FASCRS; Dr. Conditt; Hamed Yaghini, MSc; Chris Lightcap, PhD; and Mr. McKittrick

Poster Number: GS15

Title: Novel Single-port Robotic Right Hemicolectomy Surgical Robotics Platform:  Access and Reach

Authors: Drs. Parra-Davila, Lightcap and Conditt, Mr. Yaghini and Mr. McKittrick

Poster Number: GS18 

Title: Eliminating the Fulcrum Point with a Transformative Single Port Robotic Surgery Platform

Authors: Drs. Conditt and Lightcap and Mr. Yaghini and Mr. McKittrick

Poster Number: GS19

Memic, who is sponsoring the meeting, will hold an industry product theatre titled “A Novel Approach to Robotics Assisted Vaginal Surgery” on Saturday, July 2 from 12:00-1:00 p.m. ET in Salon 1-3 during which Dr. Estape, the first surgeon in the U.S. to successfully complete a patient procedure using the Hominis System, will discuss his clinical experience with this technology and Dr. Stockwell, principal investigator of our real-world patient registry, will discuss several topics including the importance of building real-world clinical data and the history of robotic surgery such as the shift to performing hysterectomies using the transvaginal approach. The company will also host hands-on demonstrations in its on-site booth (#5) where surgeons can experience using the Hominis System firsthand and practice performing surgeries with a virtual reality simulator program to support surgeon skills training and education.

In addition, the company plans to host a special on-site event called “Project M” for employees and surgeons on Friday, July 1 at 6:00 p.m. ET in the Newport Ballroom immediately following the SRS Welcome Reception.

 

SourceMemic

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”